



**Guidelines on Core Components  
of Infection Prevention and Control  
Programmes** at the National and Acute  
Health Care Facility Level



World Health  
Organization

Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level.

ISBN 978-92-4-154992-9

© **World Health Organization 2016**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition". Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules>).

Suggested citation. Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level. Geneva: World Health Organization; 2016. Licence: *CC BY-NC-SA 3.0 IGO*.

**Cataloguing-in-Publication (CIP) data** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

# Contents

<b>Acknowledgements</b>	<b>4</b>		
<b>Acronyms</b>	<b>6</b>		
<b>Glossary of terms</b>	<b>7</b>		
<b>Declarations of interest</b>	<b>8</b>		
<b>Executive summary</b>	<b>9</b>		
<b>1 Background</b>	<b>18</b>		
<b>2 Scope and objectives</b>	<b>19</b>		
<b>3 Guiding principles</b>	<b>20</b>		
<b>4 Methods</b>	<b>21</b>		
<b>5 Important issues in infection prevention and control</b>	<b>26</b>		
<b>6 The burden of health care-associated infection</b>	<b>27</b>		
<b>7 An overview of available relevant guidelines</b>	<b>29</b>		
<b>8 Core components: Guideline recommendations</b>	<b>30</b>		
<b>Core component 1:</b> Infection prevention and control programmes	30		
1a Health care facility level	30		
1b National level	34		
<b>Core component 2:</b> National and facility level infection prevention and control guidelines	37		
<b>Core component 3:</b> Infection prevention and control education and training	40		
3a Health care facility level	40		
3b National level	43		
<b>Core component 4:</b> Health care-associated infection surveillance	44		
4a Health care facility level	44		
4b National level	48		
<b>Core component 5:</b> Multimodal strategies for implementing infection prevention and control activities	53		
5a Health care facility level	53		
5b National level	57		
<b>Core component 6:</b> Monitoring and evaluation and feedback	61		
6a Health care facility level	61		
6b National level	64		
		<b>Core component 7:</b> Workload, staffing and bed occupancy at the facility level	67
		<b>Core component 8:</b> Built environment, materials and equipment for infection prevention and control at the facility level	69
		8a General principles	69
		8b. Materials, equipment and ergonomics for appropriate hand hygiene	73
	<b>9</b>	<b>Planned dissemination and implementation of the guidelines</b>	<b>75</b>
		<b>References</b>	<b>77</b>
		<b>Annexes</b>	<b>88</b>
		I. Guidelines Development Group	88
		II. WHO Steering Group	89
		III. Systematic Reviews Expert Group	89
		IV. External Peer Review Group	89
		V. A Holmes declaration of interests	90
		<b>Web Appendices</b>	
		<b>Appendix I:</b> Core elements of effective infection prevention and control programmes in acute health care facilities: a systematic review (update of the SIGHT review)	
		<b>Appendix II:</b> Core Components for Infection Prevention and Control Programmes at the National Level: Systematic Literature review	
		<b>Appendix III:</b> Summary of an inventory of available guidance from countries and WHO regional offices	

# Acknowledgements

**The Department of Service Delivery and Safety of the World Health Organization (WHO) gratefully acknowledges the contributions that many individuals and organizations have made to the development of these guidelines.**

## **Overall coordination and writing of the guidelines**

Benedetta Allegranzi and Julie Storr (Department of Service Delivery and Safety, WHO) coordinated and led the development and writing of the guidelines and contributed to the systematic reviews. Anthony Twyman (Department of Service Delivery and Safety, WHO) provided significant input for the development and drafting of the guidelines, including contributing to the systematic reviews. Rosemary Sudan provided professional editing assistance. Thomas Allen (Library and Information Networks for Knowledge, WHO) provided assistance with the searches for systematic reviews.

## **WHO Guidelines Development Group**

The chair of the Guidelines Development Group was M. Lindsay Grayson (Austin Health and University of Melbourne, Australia).

The GRADE methodologist of the WHO Guidelines Development Group was Matthias Egger (University of Bern, Switzerland).

The following experts served on the Guidelines Development Group: An Caluwaerts (Médecins Sans Frontières/Doctors Without Borders, Belgium); Riham El-Asady (Ain Shams University, Egypt); Dale Fisher (National University Hospital, Singapore); Petra Gastmeier (Charité Universitätsmedizin, Germany); Alison Holmes (Imperial College London, United Kingdom [UK]); Kushlani Jayatileke (Sri Jayewardenapura General Hospital, Sri Lanka); Mary-Louise McLaws (University of New South Wales, Australia); Geeta Mehta (Journal of

Patient Safety and Infection Control, India); Shaheen Mehtar (Infection Control Africa Network, South Africa); Babacar Ndoye (Infection Control Africa Network, Senegal); Fernando Otaíza (Ministry of Health, Chile); Maria Clara Padoveze (University of Sao Paulo, Brazil); Benjamin Park (Centers for Disease Control and Prevention, United States of America [USA]); Pierre Parneix (South-West France Healthcare-Associated Infection Control Centre, France); Didier Pittet (University of Geneva Hospitals and Faculty of Medicine, Switzerland); Valerie Robertson (Infection Control Association of Zimbabwe, Zimbabwe); Nanah Sesay-Kamara (Ministry of Health and Sanitation, Sierra Leone); Wing Hong Seto (University of Hong Kong, Hong Kong SAR, China); Maha Talaat (Infection Control Unit, United States Naval Medical Research Unit and WHO Collaborating Centre, Egypt); Akeau Unahalekhaka (Chiang Mai University, Thailand); Evangelina Vazquez Curiel (WHO Patients for Patient Safety Advisory Group Member, Mexico); Walter Zingg (University of Geneva Hospitals and Faculty of Medicine/WHO Collaborating Centre on Patient Safety, Switzerland).

## **Members of the Systematic Reviews Expert Group**

The following experts served on the Systematic Reviews Expert Group (names of team leaders are underlined): Benedetta Allegranzi, Julie Storr, Nizam Damani, Claire Kilpatrick and Anthony Twyman (Department of Service Delivery and Safety, WHO); Walter Zingg (University of Geneva Hospitals and Faculty of Medicine/WHO Collaborating Centre on Patient Safety, Switzerland); Jacqui Reilly and Lesley Price (Glasgow Caledonian University, UK); Karen Lee (University of Dundee, UK). Safia Mai Hwai Cheun, Barbara Ducry, Irene Garcia Yu and Yu Yun (Department of Service Delivery and Safety, WHO) contributed to the systematic reviews and the inventory.

## **WHO Steering Group**

Benedetta Allegranzi, Edward Kelley, Hernan Montenegro von Mühlenbrock, and Shams B. Syed (Department of Service Delivery and Safety); Sergey Eremin and Carmem Lúcia

Pessoa da Silva (Department of Pandemic and Epidemic Diseases); Ali Mafi (WHO Regional Office for the Eastern Mediterranean); Margaret Montgomery (Water, Sanitation and Health; Family, Women's and Children's Health, WHO); Valeska Stempliuk (Pan American Health Organization/WHO).

### **External Peer Review Group**

Hanan Baky (King Saud Bin Abdulaziz University for Health Sciences, Kingdom of Saudi Arabia); Michael Borg (Mater Dei Hospital, Malta); Jonas Gonseth Garcia (Abel Gilbert Pontón Hospital, Ecuador); Carolina Giuffré (Argentine Association of Infection Control Nurses; British Hospital of Buenos Aires, Argentina); Nordiah Awang Jalil (University Kebangsaan Malaysia Medical Centre, Malaysia); Folasade Ogunsola (University of Lagos, Nigeria).

### **Acknowledgement of financial support**

Funding for the development of these guidelines was mainly provided by WHO. Substantial additional funds were also available through the Emergency Grant Aid kindly provided by the Government of Japan in response to the Ebola virus disease outbreak in West African countries, and through the Fleming Fund kindly provided by the UK Government to support implementation of the Antimicrobial Resistance Global Action Plan. However, the views expressed do not necessarily reflect the official policies of the Japanese or UK governments.

# Acronyms

<b>AMR</b>	antimicrobial resistance
<b>CINAHL</b>	Cumulative Index to Nursing and Allied Health Literature
<b>EMBASE</b>	Excerpta Medica Database
<b>EPOC</b>	Effective practice and organisation of care
<b>GDG</b>	Guidelines Development Group
<b>GRADE</b>	Grading of Recommendations Assessment, Development and Evaluation
<b>HAI</b>	health care-associated infection
<b>ICROMS</b>	Integrated quality criteria for review of multiple study designs
<b>ICU</b>	intensive care unit
<b>IHR</b>	International Health Regulations
<b>IPC</b>	infection prevention and control
<b>LMICs</b>	low- and middle-income countries
<b>MRSA</b>	methicillin-resistant <i>Staphylococcus aureus</i>
<b>PICO</b>	Population (P), intervention (I), comparator (C) and outcome(s) (O)
<b>PRISMA</b>	Preferred reporting items for systematic reviews and meta-analyses
<b>RCT</b>	randomized controlled trial
<b>SDG</b>	Sustainable Development Goals
<b>SIGHT</b>	Systematic review and evidence-based guidance on organization of hospital infection control programmes
<b>SSI</b>	surgical site infections
<b>UK</b>	United Kingdom
<b>USA</b>	United States of America
<b>WASH</b>	Water sanitation and hygiene
<b>WHO</b>	World Health Organization

## Glossary of terms

**Acute health care facility:** A setting used to treat sudden, often unexpected, urgent or emergent episodes of injury and illness that can lead to death or disability without rapid intervention. The term *acute care* encompasses a range of clinical health care functions, including emergency medicine, trauma care, pre-hospital emergency care, acute care surgery, critical care, urgent care and short-term inpatient stabilization.

**Alcohol-based handrub:** An alcohol-based preparation designed for application to the hands to inactivate microorganisms and/or temporarily suppress their growth. Such preparations may contain one or more types of alcohol and other active ingredients with excipients and humectants.

**Bundle:** An implementation tool aiming to improve the care process and patient outcomes in a structured manner. It comprises a small, straightforward set of evidence-based practices (generally 3 to 5) that have been proven to improve patient outcomes when performed collectively and reliably.

**Good practice statement:** A code of conduct that aims to provide a clear and simple overview of the principles, policies and practices required to implement effective measures for infection prevention and control.

### Grading of Recommendations

**Assessment, Development and Evaluation (GRADE):** an approach used to assess the quality of a body of evidence and to develop and report recommendations.

**Health care-associated infection (also referred to as “nosocomial” or “hospital infection”):** An infection occurring in a patient during the process of care in a hospital or other health care facility, which was not present or incubating at the time of admission. Health care-associated infections can also appear after discharge. They represent the most frequent adverse event associated with patient care.

**Health care-associated infection point prevalence:** The proportion of patients with one or more active health care-associated infections at a given time point.

**Health care-associated infection incidence:** The number of new cases of health care-associated infections occurring during a certain period in a population at risk.

**Improved water source:** Defined by the WHO/UNICEF Joint Monitoring Programme as a water source that by its nature of construction adequately protects the source from outside contamination, particularly faecal matter. Examples include: public taps or standpipes, protected dug wells, tube wells or boreholes.

Source: WHO/UNICEF. Progress on sanitation and drinking water: 2015 update and MDG assessment, 2015 ([http://files.unicef.org/publications/files/Progress\\_on\\_Sanitation\\_and\\_Drinking\\_Water\\_2015\\_Update\\_.pdf](http://files.unicef.org/publications/files/Progress_on_Sanitation_and_Drinking_Water_2015_Update_.pdf)).

**Improved sanitation facilities:** Toilet facilities that hygienically separate human excreta from human contact. Examples include flush/pour flush to a piped sewer system, septic tank or pit latrine, ventilated pit latrine, pit latrine with slab or composting toilet.

**Low- and middle-income countries:** WHO Member States are grouped into income groups (low, lower-middle, upper-middle, and high) based on the World Bank list of analytical income classification of economies for fiscal year 2014, calculated using the *World Bank Atlas method*. For the current 2016 fiscal year, low-income economies are defined as those with a gross national income per capita of US\$ 1045 or less in 2014; middle-income economies are those with a gross national income per capita of more than US\$ 1045, but less than US\$ 12 736; high-income economies are those with a gross national income per capita of US\$ 12 736 or more. (Lower-middle-income and upper-middle-income economies are separated at a gross national income per capita of US\$ 4125.)

**Multimodal strategy:** A multimodal strategy comprises several elements or components (three or more; usually five, <http://www.ihi.org/topics/bundles/Pages/default.aspx>) implemented in an integrated way with the aim of improving an outcome and changing behaviour. It includes tools, such as bundles and checklists, developed by multidisciplinary teams that take into account local conditions. The five most common components include: (i) system change (availability of the appropriate infrastructure and supplies to enable infection prevention and control good practices); (ii) education and training of health care workers and key players (for example, managers); (iii) monitoring infrastructures, practices, processes, outcomes and providing data feedback; (iv) reminders in the workplace/communications; and (v) culture change within the establishment or the strengthening of a safety climate.

## Declarations of interest

**In accordance with WHO policy, all members of the Guidelines Development Group (GDG) were required to complete and submit a WHO Declaration of Interest form before each meeting. External reviewers and experts who conducted the systematic reviews were also required to submit a Declaration of Interest form. The secretariat then reviewed and assessed each declaration. In the case of a potential conflict of interest, the reason was presented to the GDG.**

According to the policy of the WHO Office of Compliance, Risk Management and Ethics, the biographies of potential GDG members were posted on the internet for a minimum of 14 days before formal invitations were issued. Further guidance of this office, also adhered to, included undertaking a web search of all potential members to ensure identification of any possibly significant conflicts of interest.

The procedures for the management of declared conflicts of interests were undertaken in accordance with the WHO Guidelines for declaration of interests (WHO experts). When a conflict of interest was considered significant enough to pose a risk to the guideline development process or reduce its credibility, the experts were required to openly declare such a conflict at the beginning of the Technical Consultation. However, the declared conflicts were considered irrelevant on

### **The following interests were declared by GDG members:**

Mary-Louise McLaws declared that Johnson & Johnson and Deb Australia provided a grant of 70 000 Australian dollars for the production of a video on hand hygiene in 2015. Deb also provided automated alcohol-based handrub dispensers for a study on hand hygiene in 2015. In 2014, Witheley Industries provided 10 000 Australian dollars for the bursary of a student conducting research on hand hygiene. In 2012, Gojo provided about 10 000 Australian dollars for laboratory testing used for a research study.

Petra Gastmeier, Director of the Institute of Hygiene and Environmental Medicine (Berlin) declared that her institution received financial contributions from companies producing alcohol-based handrubs (Bode, Schülke, Ecolab, B.Braun, Lysoform, Antiseptica, Dr. Schumacher, and Dr. Weigert) to support the German national hand hygiene campaign (approximately € 60 000 between 2014 and 2015).

Val Robertson declared that she received a research grant of 3000 US dollars from the International Federation of Infection Control in 2015 and that she currently receives a monthly honorarium of 2241 US dollars as a technical advisor to the Zimbabwe Infection Prevention and Control Project.

Alison Holmes declared to be a member of several scientific committees and advisory boards and to be the principal investigator for a number of projects for which her unit receives funds (see Annex V).

**预览已结束，完整报告链接和二维码如下：**

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_26772](https://www.yunbaogao.cn/report/index/report?reportId=5_26772)

